Group 1 - The core viewpoint of the article indicates that Wenzhi Traditional Chinese Medicine submitted its Hong Kong IPO prospectus on July 29, 2025, which will expire on January 29, 2026, with Haitong International as the sole sponsor. This marks the company's second failed submission [1] Group 2 - Wenzhi Traditional Chinese Medicine has established a comprehensive TCM business layout to meet customer needs ranging from disease treatment and health care to learning and practicing TCM [2] - During the reporting period, the company generated revenue through TCM medical services, TCM lifestyle products (including various TCM health products and knowledge products), and TCM brain subscription services [2] - According to a report by ZhiShi Consulting, Wenzhi Traditional Chinese Medicine is the largest provider of AI-assisted TCM medical services in mainland China for 2023 and 2024, with market shares of 1.5% and 1.3%, respectively [2] - The AI-assisted TCM medical service market is a sub-market that is expected to account for 1.4% of the overall TCM medical service market in mainland China by 2024 [2]
新股消息 | 问止中医港股IPO招股书失效
智通财经网·2026-01-29 03:33